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The cellular prion protein (PrPC) can act as a cell-surface
receptor for-amyloid (A) peptide; however, a role for PrPC in
the pathogenesis of Alzheimer’s disease (AD) is contested.Here,
we expressed a range of A isoforms and PrPC in theDrosophila
brain.We found that co-expression ofA andPrPC significantly
reduces the lifespan, disrupts circadian rhythms, and increases
A deposition in the fly brain. In contrast, under the same con-
ditions, expression of A or PrPC individually did not lead to
these phenotypic changes. In vitro studies revealed that substoi-
chiometric amounts of PrPC trap A as oligomeric assemblies
and fragment-preformed A fibers. The ability of membrane-
anchored PrPC to trap A as cytotoxic oligomers at the mem-
brane surface and fragment inert A fibers suggests a mecha-
nism by which PrPC exacerbates A deposition and pathogenic
phenotypes in the fly, supporting a role for PrPC in AD. This
study provides a second animal model linking PrPC expression
with A toxicity and supports a role for PrPC in AD pathogene-
sis. Blocking the interaction of A and PrPC represents a poten-
tial therapeutic strategy.
Alzheimer’s disease (AD)3 is themost prevalent adult neuro-
degenerative disease. It affects 46 million people worldwide,
and this number is predicted to almost triple by 2050 (1). There
is abundant evidence that self-associated assemblies of -amy-
loid peptides (A) have a crucial role in initiating the patholog-
ical cascade that culminates in neuronal dysfunction and death.
A particularly toxic activity has been assigned to lowmolecular
weight, soluble oligomers of A, rather than amyloid fibrils
(2–5). The pathological mechanisms are unclear but may
include toxic interactions of the oligomers with cellular mem-
branes, perhaps inducing ion channel formation (6). In addi-
tion, a number of more-or-less specific interactions of oligo-
meric A with putative receptor proteins have been described
(7, 8). A seminal study by Laurén et al. (9) focused attention on
the prion protein (PrP) as the only high-affinity binder of A
oligomers found in a 200,000-strong human cDNA library.
The N terminus of PrPC binds to A oligomers with nano-
molar affinity (9–14), and in some model systems this interac-
tion appears to be essential for synapto- and neurotoxicity. Spe-
cifically, Gimbel et al. (13) found that transgenic mice used as a
model of A toxicity were rendered resistant to pathology if the
PrP gene was knocked out. This rescue from the damaging
effects of A was observed despite the amyloid plaque density
and glial responses being essentially identical to control PrP/
mice.Data indicating that PrP binds to assemblies of oligomeric
A in human brains (15) and that extracts from AD brain
extracts require PrP to suppress hippocampal long term poten-
tiation (10) lend support to the importance of the PrP–A
interaction inADpathogenesis (8). PrPChas also been shown to
exacerbate A impairment of synaptic plasticity (12). Further-
more, PrPC has been shown to heighten spatial memory defects
(13) and dendritic spine loss inADmousemodels (16). Further-
more, hippocampal primary culture and intrahippocampal
injection indicate that the cytotoxic effects of A oligomers are
significantly reduced for PrP-null mice (17, 18). Similar results
are seen in cell culturewhere cell lines lackingPrPC are resistant
to A toxicity (19–21). A oligomers also influence PrPC traf-
ficking and inhibit PrPC endocytosis (22). In addition, aggre-
gates fromAD brain extracts have been reported to contain A
bound to PrP (23, 24). Human genetic studies indicate that vari-
ants in PrP modify the risk for AD, specifically the Val129 poly-
morphism is protective, as compared with individuals homozy-
gous for the Met129 allele (25). Such observations suggest that
PrPC is an important acceptor/receptor for mediating the tox-
icity of A (see review in Ref. 8).
The role of PrP in the A-dependent pathogenesis of AD has
proven controversial, not least because phenotypesmay be gen-
erated in the absence of PrP in knock-out mice (26–29) and
invertebrates that lack PrP (30, 31). It seems that not all A
toxicity is governed by PrPC; however, this does not preclude an
important role for PrPC in mediating aspects of A toxicity.
Different A assemblies and locations may well have different
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modes of toxic action; therefore these conflicting observations
may simply reflect differences in genetic backgrounds and the
nature of the A-oligomers.
In mammals, PrPC is expressed at high levels and is concen-
trated at the synaptic terminals, anchored to the membrane by
a glycosylphosphatidylinositol (GPI)moiety (32). LikeA, PrPC
can also form amyloid fibers, and this conformational transi-
tion is linked to a range of transmissible spongiform encepha-
lopathies in humans and mammals (33). Mammalian cellular
prion proteins have a high structural and sequence homology
and consist of two structurally distinct domains (34). The
C-terminal domain (residues 126–231) is predominantly -
helical, whereas theCu2-bindingN-terminal half of PrPC (res-
idues 23–126) is natively disordered (35, 36).
The mechanism by which PrPC mediates A toxicity is not
well understood. In vitro, it is known that substoichiometric
quantities of PrPCmay trapA as an oligomeric conformer and
inhibit its progression to amyloid fibers (14). Furthermore,
PrPC can also disassemble preformed A40 fibrils (14) or favor
lateral association of fibers (37). It appears that the unstruc-
tured N-terminal residues 23–126 are sufficient to inhibit A
fiber formation (14, 37, 38), although surprisingly others have
indicated that the structured C terminus of PrPC inhibits fiber
elongation (39). The binding of A oligomers to PrPC at the cell
surface may itself be sufficient to mediate A toxicity; alterna-
tively PrPC may also mediate A’s interactions with other pro-
teins such as the N-methyl-D-aspartate receptor (40), Fyn
kinase (16), and mGlu5 (41).
Our approach has been to investigate the interaction
between A and the mammalian PrPC by reconstituting a
mammalian system in an organism that is normally naïve to
both components. Extensive work (42–47) has shown that the
quantitative measurement of A-related phenotypes in flies,
such as longevity and locomotor performance, correlates with
the tendency of A peptides to form oligomeric species (31, 48,
49). The fly model of A toxicity has also provided insights into
the mechanism of the sleep–wake dysrhythmia experienced by
patients with AD (50). Similarly, the fly can be used to recreate
PrP-mediated pathology (51), and furthermore, flies expressing
ovine PrP are sensitive to scrapie brain extracts, and the PrPSc
generated in the fly can transmit prion infection to other trans-
genic flies (52–54).
Combining both A and PrP expression in the normally
naïve brain of a fruit fly offers a powerful tool for measuring the
potential of these proteins to show synergistic phenotypic
enhancements. In particular, we show co-expression of A and
PrPC enhancing both longevity and circadian behavioral defi-
cits in our flymodel, under conditionswhere each protein alone
has no effect.
Results
Co-expression of PrPC and A results in reduced longevity in
Drosophila
We used Drosophila as a model organism to look for in vivo
interactions between A andmammalian PrPC in a system that
is normally naïve to both proteins.When flies have low levels of
transgene expression—that is when cultured at 25 °C with sin-
gle copy transgenes—neither the expression of mammalian
PrPC nor the less neurotoxic A isoforms (A40 and A42)
alone reduced the lifespan of the flies. As expected, the highly
aggregation prone A42Arc (E22G arctic mutant) did reduce
median survival by a third (Fig. 1 and Table 1). However, when
PrPCwas co-expressed with the sameA isoforms, in each case
therewas a significant decrease in the longevity of the flies. This
effect was clearly synergistic for the combinations of PrPC with
A40 or A42 (Fig. 1,A and B). In all cases the PrP-A- interac-
tions significantly reduced median survival as compared with
the flies expressing either of the proteins alone, the effect being
mostmarked for the interaction of PrPCwith A42 andA42Arc
(Fig. 1, B and C) where median survival times were halved
(Table 1). The median survival times are presented in Fig. 1D
wheremedian data points represent vials of 10 flies, with a total
of 400 flies/condition.
The co-expression of Awith PrP disrupts circadian rhythm
One of the earliest features of AD and the fly model of A
toxicity is a progressive disruption in circadian rhythms, in par-
ticular the normal daily sleep–wake pattern. Previous studies
have shown that high pan-neuronal A expression in the fly
results in sleep fragmentation, nocturnal locomotor activity,
and a consequent reduction in the robustness of the circadian
locomotor oscillation (50, 55). To look for an interaction
between PrP and A in such circadian phenotypes, we
entrained flies for 3 days to a 12-h light:12-h dark cycle and then
followed their circadian locomotor activity for a further 6 days
in constant darkness using a beam-breaking actimeter. The
expression of PrPC, A40, and A42 alone did not reduce the
circadian locomotor cycle, with essentially all the flies retaining
a robust rhythm (representative actograms for the interaction
of PrPC and A42 are shown in Fig. 2,A–D). The co-expression
of PrPC with all A isoforms resulted in a more marked reduc-
tion in rhythmicity in all cases (Fig. 2,E and F). In particular, the
combination of PrPC with A42 caused disrupted sleep–wake
patterns in 55% of the flies. The highly aggregation prone
A42Arc, even in the absence of PrP, disrupted the cycle in 17%
of flies.
The presence of PrPC increases and localizes A deposits
Next, we investigated how the expression of PrPC affects the
build-up of A deposits in Drosophila brain. We immuno-
stained the brains of 20-day-old flies for A deposits, looking
for differences linked to the co-expression with PrPC. The 6E10
antibody (56) was used because its N-terminal epitope should
be available in all A conformers, including monomer, oli-
gomer, and fibril. In the absence of PrPC, only A42Arc showed
some A deposits, accounting for 10% of the area of the brain
section. By contrast, the co-expression of PrPC boosted the dep-
osition of A42Arc greatly, resulting in positive staining over
60% of the section area. There was a synergistic interaction
between PrPC and A42, whereby neither of the transgenes
alone resulted in any A deposition, but together moderate
levels of A deposition occurred, accounting for 20% of the
section area. The A deposits are observed throughout the fly
brain (Fig. 3).
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J. Biol. Chem. (2018) 293(34) 13090–13099 13091
 at U
CL Library Services on M
ay 15, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
The direct interaction of PrPC and A in the fly brain was
demonstrated by immunoprecipitation using the Sha31 anti-
PrP antibody (57) with subsequent Western blotting with the
6E10 anti-A antibody. Head extracts from flies expressing
A42 or A42Arc, in the presence of PrPC, revealed a specific A
band on the Western blotting (Fig. 3C). Control experiments
where either PrPC or A was not expressed in the flies did not
yield a band. The A band suggests PrP binds to small SDS
resistant oligomers.
In vitro, micromolar concentrations of PrP(23–231) inhibit A
fiber formation and fragment existing fibrils, promoting A
oligomers
The amyloid-specific fluorescent dye thioflavin T (ThT) and
transmission EM (TEM) were employed to probe the influence
of PrPC on A assembly in vitro. For 5 M monomeric A42 or
A42Arc, the time-dependent ThT signal was characteristic of a
nucleated polymerization reaction consisting of an initial lag-
phase followed by a rapid burst phase caused by amyloid fiber
elongation (Fig. 4, A and B). At equilibrium, TEM images con-
firmed the presence of fibers for both A42 (Fig. 4C) and
A42Arc (Fig. 4D). When 2.5M of full-length PrP(23–231) was
added at the start of the reaction, theThT signalwas completely
suppressed for A42 and greatly reduced for A42Arc (Fig. 4, A
and B, red traces). Under these conditions, TEM revealed
largely the presence of spherical oligomeric A assemblies typ-
ically 10–20 nm in diameter (Fig. 4, E and F). Furthermore, the
addition of 5 M PrP(23–231) to a preparation of A-amyloid
fibers resulted in a 40–50% reduction in the ThT fluorescence
signal, suggesting disruption of the preformed fibrils. TEM
reveals a heterogeneous mixture of assembles; there were few
mature fibrils. However, some structures appeared to be dis-
rupted fibers, 10–20 nm wide and typically 100–200 nm long;
other structures resembled circular A oligomers similar to
those in Fig. 4 (E and F). The fragmented short fiber rods tended
to become laterally associated, a feature reported previously for
short fragmented fibers (58, 59).
Discussion
Although there is strong evidence from a number of labora-
tories to link some aspects of A neurotoxicity and subsequent
AD pathology with the presence of the cellular prion protein
(PrPC) (8–10, 12, 13, 16, 40, 41), its precise role inADpathology
remains controversial (26, 29). There is a longstanding lack of
consensus regarding the pathogenic role of PrPCwithinmurine
model systems; we therefore chose to use Drosophila as an
alternative experimental organism. The A-expressing fly has
been shown to directly report oligomeric toxicity, principally
through experiments correlating various quantitative pheno-
types with the in vitro aggregation behavior of a range of A
isoforms (42–46). Likewise, the PrP-expressing flies have been
Figure1.AandPrPC interact to reduce longevity inDrosophila.A–C, the effects on longevitywhen co-expressingPrPCwithA isoforms: A40 (A), A42 (B),
and A42Arc (C). The co-expression of PrPwith A (red), PrP only (orange), A only (blue), and nontransgenic control flies 51D/51D (black) is shown. Co-expres-
sion of Awith PrP causes a significant reduction in longevity particularly for A42 and A42Arc flies. Each survival assay used 100 flies repeated four times; in
total 400 flies/genotype were used. D, scatter plot showing the median survival of each vial of 10 flies, with 40 vials for each genotype. *, p  0.05; ns, no
significant difference.
Table 1
Longevity assays for eight genotypes
The number of median days of survival is shown. 400 flies were used for each
genotype. The standard deviation was calculated from variation in values for vials
containing 10 flies (n 40).
51D PrPC
51D 62 7 65 8
A40 70 6 51 8
A42 69 5 36 5
A42Arc 44 5 20 2
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well characterized by Thackray et al. (51), who have systemat-
ically investigated the cellular localizations of transgenic PrP in
Drosophila. Notably, using immunocytochemistry, they show
that WT mouse, hamster, and sheep PrP are all expressed on
the surface ofDrosophila S2 cells in culture.Using the same flies
that we studied here, immunohistological examination of the
PrP-expressing fly brain following scrapie prion infection is
consistent with normal GPI-anchored surface expression and
results in deposition of protease-resistant PrPSc along with vac-
uolation (53). They also show that altering the localization of
the PrP, by removing the secretion signal peptide or the GPI
anchor sequence, results in alterations in both neurotoxicity
and prion susceptibility in this fly model (54). Thus, the fly has
several advantages for studying the interaction of PrPC and A,
not least because there is no endogenous production of similar
proteins. For this reason, the fly is unlikely to possess a con-
served signaling pathway downstream of PrPC, potentially
making the mechanism of any synergistic toxic interaction less
complex. Specifically, the fly is well suited to the in vivo study of
changes in the biophysical state of A consequent upon its
interaction with PrPC, which is anchored by GPI to the cellular
membranes within in the brain of the fly (52).
The consistent finding in both the longevity and circadian
behavioral assays is that the interactions between PrPC and
both A40 and A42 are synergistic, because phenotypes only
emerge when both proteins are co-expressed. Specifically,
when the transgenes are expressed at low levels, lines express-
ing each protein alone show no deficits. Under the same condi-
tions with both A and PrPc expressed together, there is a
marked reduction in longevity and loss of circadian rhythmic-
ity. Importantly, the extent of synergistic interaction between
A and PrPC correlates well with the propensity of the various
A isoforms to spontaneously generate oligomeric assemblies
in AD. Specifically, A42 and A42Arc peptides, by producing
oligomeric ligands, are best suited to interact with PrPC, which
results in a heightened phenotype.
Previous studies have established that A oligomers bind
PrPC with nanomolar affinity (9, 11). Here our co-immunopre-
cipitation studies show that A and PrPC are interacting
directly in the Drosophila brain. A binds to the unstructured
N terminus of PrPC (9, 11, 14, 37, 38), and substoichiometric
PrPC will inhibit A40 and A42 fiber formation while promot-
ing oligomer generation (14). We have previously shown that
these PrPC trapped oligomers have a high -sheet content and
Figure 2. A and PrPC interact to degrade circadian rhythmicity in aDrosophilamodel. A–D, four actograms showing the average locomotor activity of a
groupof typically 16Drosophilamales for each genotype.A, WT (51D/51D). B, PrP only.C, A42 only.D, PrPA42. Flieswere entrained in a 12-h light:12-h dark
cycle up today 12 and thereaftermaintained in continuousdarkness. Thedata arepresented for days 12–18. E, rhythmicity statistic for the indicatedgenotypes
and n number: 51D/51D, n  35; 51D/A40, n  42; 51D/A42, n  38; 51D/A42Arc, n  51; 51D/PrP, n  44; PrP/A40, n  41; PrP/A42, n  49; and
PrP/A42Arc,n 20. Loss of rhythmicity is significant for the PrPA crossed flies. ***,p 0.001; **,p 0.01. F, the percentageof flies/genotype that retained
circadian rhythmicity. The A PrP crossed flies (red shades) have marked loss in rhythmicity. The y axis shows the percentage of rhythmicity1.5.
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Figure 4. In vitroA42 andA42Arc fiber formation inhibited by the presence of PrP
C. A and B, fiber formation kinetics of A42 and A42Arcmonitored by
ThT fluorescence; in the absence of PrPC (blue) or in the presence of 0.5molar equivalents of PrPC (red) and 1molar equivalents of PrPC added tomature fibers
(black). The arrow highlights the point at which PrPC was added to mature A fibers. C and D, negative stain TEM images of A42 fibers (C) and A42Arc fibers
(D). E and F, A42 incubated in the presence of 0.5 molar equivalent of PrP(23–231) (E) and A42Arc with PrP
C (F). Scale bar, 100 nm.
Figure 3. PrPC promotes A accumulation inDrosophila brain by direct interaction. A, a comparison of A-expressing flies with PrP (top row) or without
PrP co-expression (bottom row). Anti-A antibody (green) was used to identify all Adeposits, and an anti-pigment dispersing factor antibody (magenta) stains
throughout fly brain including central brain (CB) and its optic lobe (OL); each image box is 250 250 m. B, a plot presenting the fraction of A positive area
for Drosophila brain sections, 10 flies/construct. C, co-immunoprecipitation indicates direct A–PrP interaction in the fly brain extracts. SDS Western blotting
was carriedout usingSE16, the anti-A antibody; the complexwasprecipitatedusingSha31, the anti-PrP antibody. TheWesternblotting shown is forA42–PrP
and A42Arc–PrP co-expressing flies, together with control flies expressing single transgenes.
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bind the A-oligomer specific A11 antibody (14). These A42
oligomers have been further characterized by cryo-TEM,which
shows they form nanotubes (60). These cylindrical structures
may be capable or penetrating the lipid bilayer to form toxic
ion-channel pores (6). We show here PrPC will also inhibit the
formation of fibrillar A42Arc, favoring instead oligomeric
assemblies, like those observed for A42. There is a body of
evidence indicating that small soluble A42 oligomers rather
than fibers are the cytotoxic form of A (2–5), perhaps capable
of forming ion channels (6). The ability of PrPC to act as a cell
surface receptor for A oligomers capable of trapping A
assemblies in an oligomeric form, in close proximity to the
membrane, suggests a mechanism by which GPI membrane-
anchored PrPC can help facilitate A membrane interaction,
which could then cause a loss of membrane integrity.
Remarkably, PrPC is capable of rapidly impacting the struc-
ture of preformed A42 fibers, causing them to fragment. This
fragmentation of fibers increases the number of fiber ends/unit
length of fiber, whichmay increase cytotoxicity and is also likely
to promote seeding of A assemblies in the fly brain (61). The
6E10 antibody used to detect A in the fly brain reports both
oligomeric and fibrillar conformers; however, the increased
deposition, with accompanying toxicity, is consistent with PrP-
trapped oligomer formation. Such stabilization of oligomeric
assemblies is supported by our in vitro experiments showing
that for both A42 and A42Arc, the interaction with PrPC
results in the generation of potentially toxic oligomeric aggre-
gates irrespective of whether the initial A conformer is mono-
meric or fibrillar. Taken together, this study predicts that PrPC
potentiates AD pathogenesis. In the early stages, it encourages
initial neurotoxic oligomer formation. Later in the disease, we
would predict that the PrP–A interaction should destabilize
otherwise inert amyloid plaques, potentially releasing toxic
amyloid fragments and favoring proteopathic seeding.
There is also a possibility that the presence of A induces
PrPC tomisfold, self-associate, and become cytotoxic, although
this is not seen in clinical specimens (62). Indeed, recently it has
been shown that A will instead inhibit PrP fiber formation
(63). Furthermore, we show here that the degree of phenotype
enhancement in the fly is determined by which A isoform is
presentA40A42A42Arc, indicating that theA isoform
influences toxicity in the fly model. This does preclude PrPSc
driving the toxic action, but it is clear the co-expression of PrPC
promotes A deposition in the fly brain and A oligomer for-
mation in vitro.
A number of other amyloidogenic proteins can co-aggregate
or influence assembly pathways of each other (64, 65). In par-
ticular both -synuclein and islet amyloid polypeptide have
been shown to interact with A (66–68), while different iso-
forms of A can also profoundly impact each other’s fiber
assembly (58, 59).
The loss of circadian rhythms and reduced life span of A
PrP co-expressing flies strongly supports a role for PrPC in A
neurotoxicity in this model of AD. These data fromDrosophila
add to the murine studies and further support a crucial role for
PrPC in the pathogenesis of AD. In vitro, PrPC binds to A
oligomers trapping A assemblies in an oligomeric state, while
A fibers become fragmented. In vivo, this results in the accu-
mulation of A aggregates in the fly brain. Blocking the inter-
action between PrPC and A may provide a novel avenue for
AD therapy (60, 69–71).
Materials andmethods
Drosophila lines
All Drosophila UAS-responsive transgenes were introduced
into a w1118 background using pUAST/PhiC31-mediated site-
directed transgenesis at the 51D acceptor site on the second
chromosome (49). Flies expressing different A peptides were
generated as described by Crowther et al. (45). Three different
constructs of A isoform were used: A40 (residues 1–40),
A42 (residues 1–42), and the A42 arctic mutant (E22G)
A42Arc, associated with early onset familial AD. The elav c155-
GAL4 systemwas employed to express humanA and theGPI-
anchored ovine PrPC(23–231). The prion line was UAS-PrP,
Val136–Arg154–Gln171 (VRQ) polymorphism as described by
Thackray et al. (52). Flies expressing the transgenic proteins
pan-neuronally were generated by crossing virgin female
elavc155-GAL4 flies withmaleUAS-A andUAS-PrP. TheseA
constructs expressed as the isolated peptide were co-expressed
with the mammalian prion protein (PrPC) containing the VRQ
isoform of ovine PrP.
We measured the mRNA levels for the single and co-ex-
pressed transgenes to confirm there was no down-regulation of
A or PrP observed. The -actin levels were used as a standard
for the quantitative RT-PCR experiments. For the quantitative
RT-PCR andWestern blotting studies, a total of 50 and 35 flies
were used, respectively.
Fly rearing
All fly stocks and crossings were cultured in standard yeast
cornmeal food vials. For each crossing five male and females
were reared in the vial, with at 25 °C and 80% humidity with a
12-h light–dark (LD) cycle as described previously (45). Each
day, newly eclosed offspring carrying a transgene for A40,
A42, the E22G variant of A42 (A42Arc), and/or PrP (VRQ),
driven by elavc155-GAL4were placed in a fresh culture tube and
incubated for a further 24 h at 25 °C to ensure that the females
were mated. Control flies with WT X chromosomes (as a con-
trol for elavc155-GAL4) or the empty 51D transgenesis acceptor
site chromosome (as a control for the transgenes) were handled
in the same way. Following mating, the females were separated
and retained for longevity assays, whereas the males were used
for circadian actimetry assays.
Longevity assays
Longevity assays were performed using 100 mated female
flies as described previously (45). Each assay was repeated four
times using flies from independent genetic crosses; a total of
400 flies were used in each comparison. Surviving flies were
counted and placed in fresh culture tubes twice per week. The
datawere visualized usingKaplan–Meier survival plots, and the
statistical significance of any differences in longevity was esti-
mate using the Student’s t test, calculated using n 40 estima-
tions of the populationmedian survival. A p value of0.05 was
set as the threshold for statistical significance. Differences in
Prion-protein interaction with A in a Drosophilamodel
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longevity were analyzed using the log-rank statistical method,
using Prism software.
Circadian locomotor
Adult male flies of each genotype were aged to 9 days
after eclosion before being transferred to individual tubes and
entrained for 3 days using 12-h light:12-h dark cycles. For the
subsequent 6 days, the fly locomotor activity was monitored in
constant darkness by counting the breaks of an IR beam within
the fly tube, with counts summed every 30min (DAMmonitor-
ing system; Trikinetics, Waltham, MA). The Drosophila circa-
dian assay has been described previously (50, 74). The rhythmic
percentage is the fraction of flies that achieve a rhythmicity
statistic1.5.We quantify the strength of the circadian rhythm
using the rhythmicity index. The rhythmicity index is obtained
from the height of the third peak on the correlogram (75, 76).
The ratio of the rhythmicity index value comparedwith the 95%
confidence line gives the rhythmicity statistic value (77). The
average actograms for 16 flies were plotted using the Flytoolbox
onMATLAB for all light–dark and constant-darkness sessions.
Immunohistochemistry
Protein accumulation in fly brains were imaged by fluores-
cence microscopy using the anti-A1–16 (6E10), anti-PDF
(pigment dispersing factor), and Anti-PrP (Sha31) antibodies.
For each condition, 10 female flies were fixed in 4% w/v para-
formaldehyde (0.1 M phosphate buffer, pH 7.4, with 0.1% v/v
Triton X-100) at an age of 20 days after eclosion. After 3 h of
fixation at room temperature, the flies were washed three times
with phosphate buffer at room temperature. The Drosophila
brainswere then dissected on ice, and nonspecific protein bind-
ingwas blockedwith 10% (w/v) goat serum (in phosphate buffer
with 0.5% v/v Triton X-100) for 2 h at room temperature.
The brains were then stained using two primary antibodies:
monoclonal mouse anti-PDF (1:1000, PDFC7; Developmental
Studies Hybridoma Bank) and polyclonal rabbit anti-A1–16
(1:1000, SIG-39322; Covance) at 4 °C for 24 h. Six steps ofwash-
ing (in phosphate buffer with 0.5% v/v Triton X-100) followed
by incubation with Alexa Fluor 488–conjugated anti-mouse
and Alexa Fluor 647–conjugated anti-rabbit antibodies (both
at 1:500) overnight at 4 °C. Finally, the brains were washed six
more times,mounted inVectashield (Vector Laboratories), and
stored at 4 °C until viewed under a Nikon Eclipse C1si confocal
microscope. This protocol is modified from that described by
Hermann et al. (78). The percentage stained parameter was
calculated using ImageJ and reports the fraction of Drosophila
brain section area that stain for A.
Co-immunoprecipitation of Awith PrP
Approximately a thousand flies or more (3 cm3), expressing
A42 or A42Arc with and without PrP, were flash frozen in
liquid nitrogen and decapitated by vortexing while frozen. For
each genotype, 400 l of isolated Drosophila heads were
homogenized in 400 l of extraction buffer (20 mMHEPES, pH
7.5, 100 mM KCl, 1 mM DTT, 5% (v/v) glycerol, 0.05% (v/v)
Nonidet P40, Roche cOmplete protease inhibitor) using a snap-
top tube and disposable pestel. This fly homogenate was pre-
cleared by centrifugation at 2,000 g for 20 min to remove A
and PrP aggregates. Separately 20 l of protein G–Sepharose
fast flow beads (Amersham Biosciences) were first incubated
with anti-PrP antibody (Sha31, 5 l of undiluted). The beads
were incubated with the antibody for 1 h at 4 °C, with gentle
agitation. The beads were then washed twice with incubation
buffer and added to the Drosophila head extracts for 16 h at
4 °C. The beads were washed twice with extraction buffer
before being resuspended in 5 l of lithium dodecyl sulfate
loading buffer. The proteins were separated on a 4–20% (w/v)
gradient SDS–PAGE gel and blotted onto a nitrocellulose
membrane. The membrane was blocked in PBS containing 5%
(w/v) nonfat milk for 1 h at room temperature and incubated
with horseradish peroxidase-conjugated rabbit polyclonal anti-
A1–16 (1:1000, SIG-39322; Covance) for 1 h at room temper-
ature. After six washes in PBS, 0.05% (v/v) Triton, the blot was
incubated with a goat anti-rabbit secondary antibody and incu-
bated at room temperature for 90 min. The washing steps were
repeated, and the membrane was developed using the Super-
Signal West Femto kit. Transgene expression levels were similar
across the genotypes, as determined by qPCR. However, the A
interaction with PrP results in the accumulation of A; for this
reason, input levels of A were not measured. The loading of the
Western blotting was based on equal tissue extract per lane.
Recombinant Syrian hamster PrP expression and purification
Tag-free, full-length Syrian hamster PrP, SHaPrP-(23–231),
was cloned into a pET-23 vector and expressed in Rosetta
(DE3)pLysS Escherichia coli cells. Cultures were grown at 37 °C
to absorption at 600 nm of 0.9 AU, and protein expression was
induced by 1 mM isopropyl -D-1-thiogalactopyranoside. The
cells were grown for a further 16–18 h at 16 °C. Bacterial pellets
were lysed by sonication in resuspension buffer (150 mM NaCl
and 50mMTris-HCl, pH7.5). The soluble fractionwas removed
by centrifugation (20,000  g for 15 min), and the insoluble
fraction was resuspended in solubilization buffer (8 M urea, 150
mM NaCl, and 50 mM Tris HCl, pH 7.5). Cell debris was
removed by centrifugation (20,000  g for 15 min), and the
soluble fractionwas applied to chelating Sepharose (Amersham
Biosciences) charged with copper. The Sepharose was washed
with five column volumes of solubilization buffer and refolded
in wash buffer (100 mM NaCl, 10 mM imidazole, 50 mM Tris-
HCl, pH 7.5) containing decreasing concentrations of urea. The
protein was eluted from the column (100 mM NaCl, 0.5 M im-
idazole, 50mMTris-HCl, pH 7.5) and concentrated in a centrif-
ugal concentrator (Sartorius) with a 10-kDa molecular mass
cutoff. The protein was further purified by size exclusion chro-
matography using an S75 column (10/300 GL) attached to an
AKTA PURE (GE Healthcare). The protein was assessed to be
greater than 95% pure by SDS-PAGE (4–20% Tris-glycine gel;
Bio-Rad) and stained with InstantBlue (Expedeon). The con-
centration of ShaPrP(23–231) was measured by its absor-
bance at 280 nm using a molar absorption coefficient of
62,280 M1 cm1.
A peptide
A peptides were purchased from Cambridge Research Bio-
chemicals or EZBiolab, synthesized using Fmoc (N-(9-fluore-
nyl)methoxycarbonyl) chemistry, purified as a single peak on
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HPLC and characterized by MS. The purchased peptides
included human -amyloid peptide, residues 1–42, and the
arcticmutant E22G; designatedA42 andA42Arc, respectively.
A42 and A42Arc were solubilized at 0.7 mg/ml in water at pH
10 with gentle rocking at 4 °C for 4 h, maintaining pH 10 by
addition of NaOH. A42 and A42Arc were purified using size-
exclusion chromatography after solubilization using an S200
column, a protocol adapted from (72). The absorbance at 280
nm was used to calculate the concentration of A, with an
extinction coefficient of 1280 M1 cm1.
Fiber growth kinetics
Fiber growth kinetics was monitored using a 96-well plate
with ThT, a fiber-specific fluorescent dye. SolubilizedA42 and
A42Arc was incubated at 30 °Cwith 30mMHEPES, pH 7.4, and
160 mM NaCl, with intermittent shaking in the presence and
absence of recombinant PrPC(23–231). The growth of A
fibers was monitored using a 96-well microplate plate and a
BMGOmega FLUOstar fluorescence reader, with an excitation
filter at 440 nm and an emission filter at 490 nm. Each reading
consists of 20 flashes, prior to each reading, the plate was agi-
tated for 30 s with double orbital (200 rpm) shaking every 30
min. Sterile flat-bottomed plates were used and sealed with
Starseal polyolefin sealing film.A volume of 200l was used per
well. The pH of a sample was monitored before and after each
experiment; a variation of0.05 pH units or less was observed
over the course of the experiment. ThT additions were made
from a fresh 2 mM stock solution in water. The fibril growth
experiments were typically carried out using 5 M monomeric
A42 andA42Arc in the presence of 2molar equivalents of ThT
(73). The sample was incubated at 30 °C in the presence of 160
mM NaCl, 30 mM HEPES, pH 7.4. Fluorescence measurements
weremade from above, using an orbital averaging sample read-
ing (4-mm diameter). For the disaggregation experiments,
small aliquots of ShaPrP(23–231) were added to preformed
fibrillary A, whereas the 96-well plate was left on the plate
holder within the reader.
Transmission electronmicroscopy (TEM)
Anegative stain of phosphotungstinic acidwas used to image
A fiber/oligomers assemblies using TEM. Carbon-coated
300-mesh copper grids (SPI Supplies) were glow discharged at
the start of each experiment. 5-l aliquots of the 5 MA sam-
ple were absorbed onto each grid for 90 s before blotting dry.
The grids were washed with water followed by incubation with
5 l of 2% (w/v) phosphotungstic acid, pH 7.4, for 70 s, to pro-
duce a negatively stained A. Finally the grids were washed in
water. Images of the grids were recorded on a JEOL JEM 1230
electronmicroscope operated at 80 kV, aMorada 2kCCD cam-
era system, and the iTEM software package (Olympus Europa).
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